Myeloma News and Research

RSS

Ochsner MD Anderson Cancer Center delivers Louisiana’s first TIL therapy for melanoma

Ochsner MD Anderson Cancer Center at The Gayle and Tom Benson Cancer Center in New Orleans announces a milestone in advanced cancer treatment, as the first institution in Louisiana to provide an adult patient with tumor-infiltrating lymphocytes (TIL) therapy for advanced melanoma.

23 Feb 2026

Engineered Listeria boosts innate immunity against cancer

After nearly 40 years of research on how Listeria bacteria manipulate our cells and battle our immune system to cause listeriosis, Daniel Portnoy and his colleagues have discovered a way to turn the bacteria into a potent booster of the immune system - and a potential weapon against cancer.

13 Feb 2026

11th Innate Killer Summit returns to San Diego, showcasing clinical data that signals renewed momentum in NK cell therapy

The 11th Innate Killer Summit returns, bringing together global leaders advancing natural killer (NK) cell–based immunotherapies.

From Hanson Wade Group - 11th Innate Killer Summit 6 Feb 2026

Novel RNA molecule may influence patient survival in certain blood cancers

In a recent study published in the Proceedings of the National Academy of Sciences (PNAS), researchers at the Texas A&M University Health Science Center (Texas A&M Health) identify a novel RNA molecule that plays a crucial role in preserving the integrity of a key cellular structure, nucleolus (a dense region of the cell containing a subset of crucial genetic material).

2 Feb 2026

Antibody-producing plasma cells shape effectiveness of PD-1 immunotherapy

Scientists at the Icahn School of Medicine at Mount Sinai have identified an important immune response that helps explain why some cancer patients benefit from immunotherapy while others do not.

27 Jan 2026

Study provides a new paradigm for managing transplant‑related immune complications

Acute graft-versus-host disease (aGVHD) is one of the most serious complications after allogeneic hematopoietic stem cell transplantation (allo‑HSCT).

16 Jan 2026

Cancer mortality drops 34% as treatments and early detection improve

The 2026 cancer statistics reveal improved survival rates but highlight persistent inequities in cancer incidence and mortality across different populations.

16 Jan 2026

Multiple myeloma rates increasing twice as high in men than in women

Rates of multiple myeloma (MM), the second most common blood cancer in the United States, are increasing and are twice as high in men than in women

12 Jan 2026

Single-cell analysis illuminates myeloma immune landscape

Scientists at the Icahn School of Medicine at Mount Sinai, in partnership with the Multiple Myeloma Research Foundation (MMRF) and in collaboration with leading institutions across the country, have helped generate the largest single-cell immune cell atlas of the bone marrow in patients with multiple myeloma, a blood cancer that, while treatable, remains incurable.

9 Jan 2026

Immune cell atlas may improve survival predictions, guide treatment decisions in multiple myeloma

aps the immune cell landscape of bone marrow in patients with multiple myeloma, a rare cancer that develops in the plasma cells of the bone marrow and has no cure.

9 Jan 2026

New AI model brings precision medicine to multiple myeloma care

C. Ola Landgren, M.D., Ph.D., received HealthTree Foundation's prestigious 2025 Innovation Award for his work in developing CORAL, a new research tool that leverages AI to predict individual outcomes and guide treatment decisions in patients with multiple myeloma.

19 Dec 2025

Antibody therapy clears residual multiple myeloma in early trial

Treatment with an immune and cancer cell-targeting antibody therapy eradicates residual traces of the blood cell cancer multiple myeloma, according to interim results from a clinical trial conducted by researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

10 Dec 2025

$Tec-Dara could represent a new standard of care for relapsed or refractory multiple myeloma$

Tec-Dara could represent a new standard of care for relapsed or refractory multiple myeloma

Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific monoclonal antibody, and daratumumab, a CD38-directed monoclonal antibody, were 83% more likely to be alive without disease progression compared with those who received standard second-line therapies at a median of nearly 35 months of follow-up, according to the results of a new trial presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.

10 Dec 2025

People exposed to Agent Orange face higher risk of developing myelodysplastic syndrome

A new national study shows for the first time that people exposed to Agent Orange face a higher risk of developing myelodysplastic syndrome (MDS), tend to develop it earlier, and often have more aggressive disease that is more likely to progress to acute myeloid leukemia.

9 Dec 2025

New antibody shows ability to overcome treatment resistance in blood cancers and solid tumors

In a new preclinical study, researchers from The University of Texas MD Anderson Cancer Center developed an antibody therapy called 77A that showed an ability to overcome treatment resistance in blood cancers, such as myeloma and lymphoma, as well as solid tumors.

9 Dec 2025

Patients receiving T-cell redirecting therapies can safely be monitored at home

Patients who receive T-cell redirecting therapies are typically hospitalized for several days after treatment to watch for side effects.

9 Dec 2025

Serious side effects after CAR T cell therapy for multiple myeloma share a common immune root cause

Serious side effects, including neurotoxicity and intestinal inflammation, that appear weeks or months after patients receive CAR T cell therapy for multiple myeloma share a common immune root cause, are associated with high rates of death unrelated to cancer relapse-primarily infection-and may be avoidable.

8 Dec 2025

SISAQOL-IMI provides guidance for implementing patient-reported outcomes in cancer clinical trials

The SISAQOL-IMI consortium, co-led by the European Organisation for Research and Treatment of Cancer (EORTC) and Boehringer Ingelheim (BI), just announced the publication of its pivotal paper in The Lancet Oncology outlining how its recommendations for patient-reported outcomes (PROs) in cancer clinical trials were developed.

26 Nov 2025

Longest survival in the world reported to date for multiple myeloma patients

Berenson Cancer Center published survival data analyzed by the Institute for Myeloma & Bone Cancer Research of 175 consecutive and unselected patients with multiple myeloma in the journal Haematologica.

19 Nov 2025

Research identifies factors for long-term myeloma remission

A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of blood cancer, stay in remission for many years after receiving CAR T cell therapy, while others see their cancer return sooner.

13 Nov 2025

Myeloma News and Research

Ochsner MD Anderson Cancer Center delivers Louisiana’s first TIL therapy for melanoma

Engineered Listeria boosts innate immunity against cancer

11th Innate Killer Summit returns to San Diego, showcasing clinical data that signals renewed momentum in NK cell therapy

Novel RNA molecule may influence patient survival in certain blood cancers

Antibody-producing plasma cells shape effectiveness of PD-1 immunotherapy

Study provides a new paradigm for managing transplant‑related immune complications

Cancer mortality drops 34% as treatments and early detection improve

Multiple myeloma rates increasing twice as high in men than in women

Single-cell analysis illuminates myeloma immune landscape

Immune cell atlas may improve survival predictions, guide treatment decisions in multiple myeloma

New AI model brings precision medicine to multiple myeloma care

Antibody therapy clears residual multiple myeloma in early trial

Tec-Dara could represent a new standard of care for relapsed or refractory multiple myeloma

People exposed to Agent Orange face higher risk of developing myelodysplastic syndrome

New antibody shows ability to overcome treatment resistance in blood cancers and solid tumors

Patients receiving T-cell redirecting therapies can safely be monitored at home

Serious side effects after CAR T cell therapy for multiple myeloma share a common immune root cause

SISAQOL-IMI provides guidance for implementing patient-reported outcomes in cancer clinical trials

Longest survival in the world reported to date for multiple myeloma patients

Research identifies factors for long-term myeloma remission

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News